In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs
Eissenberg et al.
ASCO 2015
Eissenberg et al.
ASCO 2015
Reusch et al.
ASCO 2015
Reusch et al.
ASCO 2015
Weichel et al.
European Pharmaceutical Review 2015 20(1): 27-32
Rothe et al.
ASH 2014
Reusch et al.
PEGS 2014
Reusch et al.
MAbs. 2014 Mar 26;6(3).
Reiners et al.
Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5./.
Pörtner et al.
Cancer Immunol Immunother. 2012 Oct;61(10):1869-75
McAleese F, Eser M.
Future Oncol. 2012 Jun;8(6):687-95.